Melanotan I vs Melanotan II: Tanning Peptides Compared
Melanotan I and Melanotan II both stimulate melanogenesis via MC1R activation, but differ in their receptor selectivity, sexual effects, and side effect profiles. This review compares the research evidence for both alpha-MSH analogues.
Melanotan I (afamelanotide) and Melanotan II are both synthetic alpha-MSH analogues but differ critically in receptor selectivity, clinical development history, and associated effects — including the dramatic sexual arousal profile that makes Melanotan II the parent compound of PT-141.
Alpha-MSH: The Parent Molecule
Alpha-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) is a 13-amino acid POMC-derived peptide that is the endogenous agonist of melanocortin receptors (MC1R-MC5R). Both synthetic analogues incorporate the Nle4,D-Phe7 substitution that increases potency and metabolic stability relative to native α-MSH.
Melanotan I: MC1R-Selective, EMA-Approved
Melanotan I (afamelanotide, Scenesse) is a linear analogue with relative MC1R selectivity. MC1R drives eumelanin production in melanocytes — producing dose-dependent skin darkening without UV exposure.
EMA Approval (2014): Scenesse is approved for erythropoietic protoporphyria (EPP) — a rare genetic disorder causing extreme photosensitivity and blistering from minimal UV exposure. Lane AM et al. (*NEJM*, 2015) demonstrated that subcutaneous afamelanotide implant (16 mg every 60 days) significantly reduced painful light exposure events and increased time subjects could spend outdoors.
Melanotan II: Non-Selective, Research Compound
Melanotan II is a cyclic analogue activating MC1R, MC3R, MC4R, and MC5R. This non-selective profile explains its dramatically broader effects vs Melanotan I:
- MC4R (hypothalamic): Produces sexual arousal, spontaneous erections, and nausea
- MC1R (melanocytes): Produces tanning similar to Melanotan I
- MC3R: Metabolic regulation and appetite modulation
- MC5R: Affects sebaceous gland secretion and immune function
The sexual arousal and spontaneous erection effects — observed as "side effects" in University of Arizona tanning research — led directly to development of PT-141 (Bremelanotide): a modified derivative optimised for sexual function research by reducing tanning activity.
Safety Contrast
| Feature | Melanotan I | [Melanotan II](/peptides/melanotan-ii) |
|---|---|---|
| MC4R sexual arousal effects | Minimal | Pronounced and common |
| MC4R nausea | Minimal | Common at higher doses |
| Regulatory approval | EMA (EPP indication) | Research compound only |
| Pigmentation risk | Stimulates all melanocytes | Same risk |
A shared safety concern: both compounds may stimulate pre-existing pigmented lesions and melanocytic naevi — requiring caution in individuals with mole-prone or high-UV-exposure skin histories.
Melanotan II is not approved for human use anywhere. Melanotan I/afamelanotide is EMA-approved for EPP only. Both carry significant risks outside medical supervision.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.